The current gold standard treatment for AATD is augmentation therapy utilizing AAT sourced from pooled human plasma at a dose of 60 mg/kg, administered by slow intravenous infusion once weekly. Here, SERPINA1 is linked to alpha 1-antitrypsin deficiency.